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Abstract 
Background: Gene expression profiling from blood is sensitive to technology choices. For example, the main blood 
RNA collection systems—the PAXgene and Tempus tubes—differently influence RNA expression signatures. The 
aim of this study was to establish a common RNA isolation protocol for these two systems and investigate if it could 
reduce the differences in gene expression between them.
Results: We collected identical blood samples on the PAXgene and Tempus systems and retrieved blood samples 
from two independent biobanks—NOWAC and HUNT3—which are based on PAXgene and Tempus, respectively. 
High-quality RNA was extracted from both sampling systems by using their original protocols and our common 
modified protocol, and were profiled on Illumina microarrays. Regardless of the protocol used, we found most of the 
measured transcripts to be differently affected by the two sampling systems. However, our modified protocol reduced 
the number of transcripts that were significantly differentially expressed between PAXgene and Tempus by approxi-
mately 50%. Expression differences between PAXgene and Tempus were highly reproducible both between protocols 
and between different independent sample sets (Pearson correlation 0.563–0.854 across 47323 probes). Moreover, the 
modified protocol increased the microRNA output of the system with lowest microRNA yield, the PAXgene system.
Conclusions: Most transcripts are affected by the choice of sampling system, but these effects are highly reproduc-
ible between independent samples. We propose that by running a control experiment with samples on both systems 
in parallel with biologically relevant samples, researchers may adjust for technical differences between the sampling 
systems.
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Background
Blood-based gene expression profiling is a valuable utility 
in biomarker analysis. Samples of blood are easily avail-
able, essentially non-invasive, and can be collected at a 
low cost, all of which makes blood samples attractive for 
diagnostic purposes. Peripheral blood is the main route 
for transportation of immune cells and thereby provides 
a window for monitoring activity of the immune system 
[1–4]. Indeed, presence of disease [5–10], prognostic 
information [11, 12] and effect on therapeutic response 
[13] have been found to be reflected in the gene expres-
sion pattern of blood cells.
The two main commercial systems for the isolation of 
high-quality RNA from blood are the PAXgene Blood 
RNA System (PreAnalytiX QIAGEN/BD, Hombrech-
tikon, Switzerland) and the Tempus Blood RNA System 
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(Applied Biosystems, Foster City, CA, USA). These two 
systems use proprietary reagents that intend to stabilize 
RNA and ensure gene expression profiles that reflect the 
blood’s state at the moment of sampling. Even though 
both sampling systems have the same purpose, they 
result in gene expression profiles that differ between the 
systems [14–16]. The recommendation from earlier stud-
ies is to avoid the mixed use of these sampling systems in 
the same experiment [14–16]. Unfortunately, this strat-
egy restricts studies that may be based on combining 
existing biobanks to biobanks that use identical sampling 
systems. Moreover, when assessing reproducibility of 
blood gene expression profiles, one should ideally include 
and test independent cohorts irrespective of their sam-
pling systems.
As the PAXgene and Tempus systems recommend 
different protocols to isolate RNA (PreAnalytiX, and 
Applied Biosystems, respectively), we set out to inves-
tigate if the use of a common protocol could reduce 
some of the differences between the two sampling sys-
tems. We developed a protocol that could isolate both 
microRNA (miRNA) and messenger RNA (mRNA) 
into the same batch, and that could be used with both 
PAXgene and Tempus tubes. Although this protocol 
still results in differences in gene expression profiles 
between the two sampling systems, we show that the 
differences are reduced compared to the original proto-
cols and that the differences are reproducible between 
cohorts. These results suggest that our setup with a 
control experiment can be used to estimate and correct 
for the effects of the technical differences between the 
two sampling systems.
Results and discussion
Previous studies have shown that the two RNA isola-
tion systems result in gene expression profiles that may 
differ significantly [14–16]. As the differences may relate 
to differences in the composition of the RNA-stabilizing 
solutions or in the isolation protocols, we wanted to test 
whether a common protocol could extract both mRNA 
and miRNA, and at the same time reduce the technical 
differences. We developed a protocol that combines ele-
ments from the original PAXgene and Tempus proto-
cols, and also includes the final steps from the mirVana 
RNA isolation protocol (Life Technologies, Carlsbad, CA, 
USA, Part Number AM1560) for isolating both mRNA 
and miRNA.
Briefly, the modified protocol processed the stabilized 
blood by removing the stabilization buffer in the tubes by 
the aid of the Tempus Spin RNA Isolation Kit protocol 
until a pellet was produced. The pellet was further puri-
fied by the use of the PAXgene protocol. The RNA was 
then rinsed by the use of the mirVana miRNA Isolation 
Kit (Life Technologies), and finally eluted in RNase free 
water (Tempus kit, Applied Biosystems). We considered 
but eventually decided not to include globin RNA reduc-
tion, as this process would have introduced more steps in 
the protocol which in turn may lead to more variation in 
the results [14, 15].
The following sections describe the comparisons of 
the original and modified protocols in terms of RNA 
yield, quality, and gene expression profiles. We used an 
experimental design consisting of three experiments that 
allowed us to assess both the differences in gene expres-
sion produced by the protocols, as well as the reproduc-
ibility of these differences between different experiments 
and cohorts (Fig. 1; Table 1).
RNA quality and quantity
RNA yield and RIN values
High quality RNA was obtained with all protocols from 
both PAXgene and Tempus tubes (Fig.  2; Additional 
file  1). The overall total RNA concentration obtained 
from the PAXgene and Tempus tubes when processed 
with the original protocols varied between the sampling 
systems (0.55 ±  0.002  ng/mL blood and 0.98 ±  0.1  ng/
mL blood, respectively), though the RNA concentra-
tion obtained from the Tempus tubes varied exten-
sively between the experimental cohorts (compare 
Exp. 1 and Exp. 2, Fig. 2a). With the modified protocol, 
the RNA concentration obtained from PAXgene tubes 
was essentially similar to that of the original protocol 
(0.55  ±  0.06  ng/mL blood), whereas the concentration 
from Tempus tubes was somewhat reduced compared 
to the original protocol (0.69  ±  0.11  ng/mL blood, all 
3 experiments, Fig.  2a). The RNA quality of the sam-
ples was generally high (RIN = 7.98 ± 0.27), with some 
variation (6.96–8.53) between protocols and tubes (all 3 
experiments, Fig. 2b).
miRNA
To detect and quantify miRNA expression, we ran 
TaqMan qPCR against hsa-miR-16-5p, hsa-miR-181-5p, 
and hsa-miR-423-3p on all samples from experiment 1 
(Fig. 2c). With the original protocols, compared with the 
Tempus samples, the PAXgene samples had significantly 
lower levels of miR-16 (log2 fold change (logFC) = −2.52, 
p = 0.01) and miR-181 (logFC = −2.51, p = 0.008), and 
reduced levels of miR-423 (logFC  =  −1.31, p  =  0.07). 
Using the modified protocol, the level of miRNAs iso-
lated from the PAXgene tubes increased significantly for 
all three miRNAs compared with the original protocol 
(Fig. 2c). For the Tempus tubes, the level of miRNAs iso-
lated with the modified protocol compared with the orig-
inal protocol differed depending on the miRNA assayed, 
though none of the differences were significant (Fig. 2c).
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Gene expression
Principal components analysis
To explore the main sources of variation in the gene 
expression profiles from the samples, we used principal 
components analysis (PCA, Additional file 2A). The main 
difference observed was between the first experiment 
and the two other experiments (PC1, Additional file 2A). 
This difference is likely a batch effect, as experiment 1 
was run separately from experiments 2 and 3. This batch 
effect was apparent in a density plot of the average probe 
intensities, which displayed a shift between the two 
runs (Additional file  2B). However, differences between 
the gene expression profiles of the PAXgene and Tem-
pus sampling systems were the second most important 
source of variation in the data (PC2, Additional file 2A). 
We explored the PCA up to six components (together 
explaining 71% of the variation in the data) without find-
ing a pattern distinguishing the original protocols from 
the modified protocol, or distinguishing between samples 
with low or high quality and quantity RNA (results not 
shown).
Comparison of RNA gene expression profiles from PAXgene 
and Tempus tubes in combination with their original 
protocols and the modified protocol
To assess differences in gene expression between PAX-
gene and Tempus tubes when used with the original 
and modified protocols, we analysed five contrasts from 
the three experiments (Fig.  1; Table  2). In experiment 
1, blood from the same individual was sampled on both 
PAXgene and Tempus tubes, and yet signals from up to 
3143 microarray probes differed significantly between 
the sampling systems (p < 0.05, Table 1), supporting ear-
lier findings [14–16]. In our analyses of all 5 contrasts, 
we found that signals from between 1440 probes (1346 
genes) to 7142 probes (6250 genes) differed signifi-
cantly between PAXgene and Tempus systems (p < 0.05, 
Table 1).
The number of probes that were differently expressed 
between the sampling systems was significantly reduced 
when the modified protocol was applied instead of the 
original protocols in experiment 1 and 2 (p  =  4.6e−07 
and p = 0.02, respectively). When comparing the signif-
icantly differentially expressed probes (p  <  0.05) for the 
original and modified protocols, we found 1066 probes 
in common in experiment 1 (Fig. 3a), and 887 probes in 
common in experiment 2 (Fig. 3b). For both experiments, 
these common probes were similarly affected by the 
sampling systems. Specifically, all the significant probes 
common for the original and modified protocols, in both 
experiments, had either consistent positive, or consistent 
negative, logFC values (Fig. 3c, d). As we used the Tem-
pus signal as reference, a positive logFC (log2 Tempus/
PAX >0) implied that the level of the probe’s target tran-
script was higher in Tempus tubes (preserved in Tem-
pus), whereas a negative logFC (log2 Tempus/PAX  <0) 
implied that the level of the probe’s target transcript was 
higher in PAXgene tubes (preserved in PAXgene).
The consistent changes in logFC values for the com-
mon probes suggested that the target transcripts for 
these probes were affected by differences in the sampling 
systems, rather than by differences in the isolation proto-
cols (Fig. 3c, d). We speculated that physical properties of 


















































Fig. 1 Study design. Differences in gene expression between 
PAXgene and Tempus were investigated in three experiments. In 
experiment 1 (light blue), four volunteers donated blood samples 
on PAXgene and Tempus tubes and RNA was isolated with both 
the original protocols and the modified protocol. Paired statistical 
analyses identified differences between PAXgene and Tempus for the 
original protocols (contrast 1) and for the modified protocol (contrast 
2). In experiment 2 (light orange), RNA was isolated with both the 
original protocols and the modified protocol from two different 
biobanks—NOWAC and HUNT3—which had samples on PAXgene 
and Tempus tubes, respectively. Non-paired statistical analyses 
identified differences between PAXgene and Tempus for the original 
protocols (contrast 3) and for the modified protocol (contrast 4). In 
experiment 3 (light green), RNA was isolated with the modified proto-
col from a larger set of samples from NOWAC and HUNT3 and a non-
paired analysis was performed (contrast 5). Comparisons between 
PAXgene and Tempus based on the original protocols are highlighted 
in orange (contrasts 1 and 3), whereas comparisons based on the 
modified protocol are highlighted in olive green (contrasts 2, 4, and 5)
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and investigated the GC content and length of their 
respective FASTA sequences. Transcripts preserved 
in PAXgene were shorter and had a higher GC content 
compared to those preserved in Tempus and all other 
annotated transcripts (Fig.  3e, f, respectively). In addi-
tion, the transcripts preserved in Tempus were signifi-
cantly overrepresented among several terms in the GO, 
KEGG and REACTOME databases, such as “activation 
and aggregation of platelets” and 52 metabolic processes, 
whereas only a few such terms (“Generic Transcription 
Pathway”, “gene expression” and 6 metabolic processes) 
were significant for the transcripts preserved in PAX-
gene (Fig. 3g). Consequently, the transcripts preserved in 
Tempus appear to have distinct physical and functional 
characteristics, whereas transcripts preserved in PAX-
gene appear to be more similar to the transcriptomic 
background.
Among the probe targets consistently preserved in 
PAXgene (logFC  <0) across protocols, a set of probes 
(n = 380) had lower logFC values for the modified pro-
tocol compared to the original protocols (Fig. 3c; points 
below the regression line). Although the transcripts tar-
geted by these probes may be more affected by the modi-
fied protocol, these transcripts were not significantly 
different from the majority of transcripts preserved in 
PAXgene in regard to GC content and transcript length. 
Furthermore, these transcripts were associated with only 
one significant REACTOME term (“Generic Transcrip-
tion Pathway”).
In summary, using the modified protocol reduces the 
number of probes significantly differentially expressed 
between the PAXgene and Tempus systems. Neverthe-
less, there are several transcripts that differ consistently 
between the two systems, independent of RNA isolation 
protocol. Both physical and biological properties of the 
transcripts appear to be relevant for the gene expression 
differences observed between PAXgene and Tempus.
Reproducible gene expression profiles from PAXgene 
and Tempus tubes in combination with their original 
protocols and the modified protocol
To assess to what extent the differences in gene expres-
sion between sampling systems were reproducible 
between different biological samples, we analysed the five 
Table 1 Contrasts produced from  comparing expression 
profiles in PAXgene and Tempus tubes
“Contrast” enumerates the five statistical comparisons specified by “Experiment” 
and “Protocol”; see Fig. 1. “Sign. probes” are the number of probes on the 
Illumina microarray (total probes: 47323) with significantly different signals in 
PAXgene compared with Tempus (* p < 0.05); “Sign. Transcripts” are the number 
of distinct transcripts targeted by the significant probes




c1 1 Original 3143 2883
c2 1 Modified 1540 1469
c3 2 Original 2236 2068
c4 2 Modified 1440 1346
c5 3 Modified 7142 6250
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Fig. 2 RNA yield and quality. Concentration (a), quality (RIN) (b), and miRNA levels (c) for RNA isolated from Tempus and PAXgene tubes with the 
original and modified protocols. Concentration and quality measurements are from all three experiments; miRNA levels are miR-16, miR-181, and 
miR-423 expression levels from experiment 1. The graphs are box-plots of the data, where the box with horizontal black line shows the first and third 
quartiles and the median; the whiskers show 1.5 times the interquartile range; and the points show outliers
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comparisons from all three experiments (Fig. 1; Table 1). 
We defined reproducible probes to have significantly dif-
ferent signals (p  <  0.05) between PAXgene and Tempus 
systems in at least two experiments.
When comparing experiment 1 and 2, the number 
of reproducible probes for the modified protocol (417; 
Table 2; Fig. 4a) was comparable to the number of repro-
ducible probes for the original protocols (711, Table  2; 
Fig.  4b). Again, we found these common probes to be 
similarly affected by the sampling systems regardless of 
protocol (Fig.  4c, d). Similar to the transcripts showing 
consistent changes irrespective of protocol, the tran-
scripts that were reproducibly preserved in the PAXgene 
tubes (logFC <0) were shorter and had a higher GC con-
tent than those preserved in the Tempus tubes (logFC >0; 
Fig.  4e, f, respectively). We also found the results from 
the GO, KEGG, and REACTOME databases to be in 
line with our earlier findings. Transcripts preserved in 
Tempus were overrepresented in number of significant 
terms compared with transcripts conserved in PAXgene 
(Fig. 4g).
As experiment 3 included a larger set of samples than 
experiments 1 and 2 (61, 4 and 13, respectively), we 
expected to have a higher statistical power to identify 
differences between PAXgene and Tempus. Indeed, we 
found more than four times as many significantly differ-
entially expressed probes in experiment 3 as in experi-
ments 1 or 2 (Fig. 5a; Table 1). This larger set of probes 
included most of the significant probes from experiment 
1 and 2 (Fig. 5b), suggesting that most of the differences 
in significant probes between these two experiments were 
due to lack of statistical power. To further investigate 
this possibility, we compared how all the 47323 probes 
on the Illumina chip (HT-12 v4) were affected by the 
sampling systems. The logFC values for all probes were 
highly correlated between experiments (Fig. 6a; Pearson’s 
r = 0.60–0.86, Additional file 3; Pearson’s r = 0.56) and 
most of the probes with high absolute logFC values were 
similarly affected between experiments. We also found 
the physical characteristics of the transcripts preserved 
in PAXgene (logFC <0) to differ from the transcripts pre-
served in Tempus (logFC >0), in agreement with our ear-
lier findings (Fig. 6b–d).
These results indicate that the differences between 
PAXgene and Tempus systems affect many probes, 
and that there is a high degree of correlation between 
experiments. To further test to what extent these differ-
ences were reproducible across studies, we compared 
the results obtained with the original protocols (experi-
ment 1) with data from a previous study by Menke et al. 
[14]. Despite some major differences with regard to study 
setup, such as subject inclusion (only men were studied 
by Menke et al.), geography, time of study, and version of 
chip used for gene expression analysis, the effects of the 
sampling systems were similar for the two experiments 
(Additional file 4; Pearson’s r = 0.27).
Collectively, these results indicate that the technical 
differences between PAXgene and Tempus systems are 
highly reproducible between different biological samples 
and experiments. In turn, this reproducibility suggests 
that the technical influence of the sampling systems on 
the gene expression profiles can be accounted for by run-
ning a control study in parallel with biologically relevant 
samples. The control study should contain RNA obtained 
from individuals sampled on both PAXgene and Tempus 
tubes, which should to be isolated and analysed together 
with the biologically relevant samples. By doing so, the 
technical differences may be estimated and subsequently 
accounted for to obtain biologically relevant gene expres-
sion profiles.
Table 2 Comparisons of results from statistical analyses (contrasts), “Focus of analysis” explains the focus of the compari-
son
“Comparison” specifies contrasts used in the comparison; see Table 1 and Fig. 1. “Direction” specifies if the significant probes (p < 0.05, Table 1) are expressed in the 
same or in the opposite direction between contrasts; hence, “Same” gives the number of probes where the logFC was positive or negative in both contrasts; “Opposite” 
gives the number of probes where the logFC was positive in one contrast and negative in the other. “Pearson” and “Spearman” give the Pearson and Spearman 
correlations, respectively, for the logFC values of all probes in the two contrasts used in the comparison
Focus of analysis Contrasts compared Direction Pearson Spearman
Same Opposite
Protocols used in exp. 1 c1 vs c2 1066 0 0.786 0.444
Protocols used in exp. 2 c3 vs c4 887 0 0.854 0.617
Reproducibility of the original protocol between exp. 1 and exp. 2 c1 vs c3 708 3 0.563 0.288
Reproducibility of the modified protocol between exp. 1 and exp. 2 c2 vs c4 417 0 0.604 0.222
Reproducibility of the modified protocol between exp. 1 and exp. 3 c2 vs c5 1199 8 0.681 0.313
Reproducibility of the modified protocol between exp. 2 and exp. 3 c4 vs c5 1330 0 0.857 0.487
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Conclusions
Several studies have claimed the two most common RNA 
stabilizing blood-sampling systems—PAXgene and Tem-
pus—to have incomparable RNA expression profiles. 
Similar to previous studies, we found that blood from the 
same individuals sampled on the PAXgene and Tempus 
systems resulted in more than 2000 genes with signifi-
cantly different expression profiles between the systems. 
Nevertheless, by developing and using a protocol applica-
ble to both PAXgene and Tempus tubes, we significantly 


































































Exp. 1 Exp. 2
dc
gf
1066 4742077 887 5531349Original
Modified


























Fig. 3 Comparison of protocols. a, b Venn diagrams showing the number of microarray probes having significantly different signals (p < 0.05) 
between PAXgene and Tempus systems for the original protocols (orange) and the modified protocol (olive) in experiment 1 (a) and experiment 2 
(b). c, d Scatter plots showing the logFC values of the 1066 and 887 significant probes found in common between the protocols in experiment 1 (c) 
and in experiment 2 (d), respectively. Grey and black lines are linear regression fits to the data and idealized regression lines (logFC original = logFC 
modified), respectively. e Length and f GC content of transcripts preserved in PAXgene (logFC <0; purple) and in Tempus (logFC >0; blue) from c and 
d. All other transcripts (“Other”; green) are included as reference. See Fig. 2 for explanation of graphs. g The number of significantly enriched biologi-
cal terms for transcripts preserved in the PAXgene and Tempus tubes
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reduced the number of genes that differed between the 
two systems (p  =  4.6e−07). Moreover, we found the 
modified protocol to improve the miRNA yield from the 
PAXgene system, which had the lowest miRNA output 
with the original protocol. Regardless of protocol used, 
however, our results indicate that the expression profile 
for a large fraction of genes is affected by the sampling 
systems. These expression profile differences were highly 
correlated between protocols and were also highly corre-
lated with the differences we found when we measured 
blood gene expression profiles of different individuals 
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Fig. 4 Reproducibility. a, b Venn diagrams showing the overlap in microarray probes having significantly different signals (p < 0.05) between 
PAXgene and Tempus systems for experiment 1 (turquoise) and experiment 2 (orange) for the original protocols (a) and the modified protocol (b). 
c, d Scatter plots showing the logFC values of the 711 and 417 significant probes found in common between experiment 1 and 2 for the original 
protocols (c) and for the modified protocol (d), respectively. e Length, f GC content, and g number of significantly enriched biological terms of 
transcripts preserved in PAXgene (purple) and in Tempus (blue) from c and d; see Fig. 2 for additional details
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and Tempus systems. Consequently, whereas the differ-
ences between the sampling systems affect a large set of 
genes, our results show that these differences are exceed-
ingly reproducible—at least when the different samples 
are analysed within the same lab. We therefore propose 
that technical differences between PAXgene and Tempus, 
when both systems are used in the same study, can be 
handled by running a control experiment with identical 
samples on both sampling systems. The gene expression 
differences identified in such a control experiment can 
then be used to correct for technical differences when 
analysing biologically relevant samples from the two 
sample systems. We expect that this approach will make 
additional cohorts available for large-scale replication 
studies or clinical gene expression research to identify 
robust, disease related biomarkers.
Methods
Study design
We did three experiments (Fig. 1) to investigate whether 
the modified protocol would reduce the differences 
in gene expression between the PAXgene and Tem-
pus sampling systems. Venous blood was drawn from 
healthy volunteers on both sampling systems and RNA 
was isolated by the use of the original protocols and/or 
the modified protocol. Since this was a study of techni-
cal issues and of no medical interest, the Regional Ethics 
Committee (REK) concluded that no approval from the 
committee was required for this part of the study (REK: 
2013/2422-2).
Experiment 1
Venous blood was collected by phlebotomy with but-
terfly needle from four healthy female volunteers (aged 
26–34) with their consent. Sampling was performed 
after 2 h of fasting and abstention from coffee, medica-
tion and exercise. Blood was collected into PAXgene 
tubes (2.5 mL blood + 6.9 mL buffer) and Tempus tubes 
(3 mL blood + 6 mL buffer). The first drawn tube from all 
participants was discarded as recommended by the PAX-
gene protocol. All samples were subsequently inverted 
10 times before being stored at −80 °C. Before isolation 
of RNA, the tubes were thawed at room temperature 
for 16  h as recommended by the PAXgene protocol for 
enhanced yields. The content of each tube was split in 
two aliquots, where one aliquot was isolated using the 
sampling systems’ original protocol and the second ali-
quot with the modified protocol (described below).
Experiment 2
Samples from healthy volunteers (aged 50–82) from two 
different biobanks were used. The Norwegian Women 
and Cancer Cohort (NOWAC) provided blood from six 
healthy females drawn on PAXgene tubes and the Health 
Survey of North-Trøndelag (HUNT3) provided blood 
from seven healthy females drawn on Tempus tubes. All 
samples arrived at our facility frozen and were stored at 
−80 °C. Before RNA isolation the tubes were thawed for 
16  h at room temperature. Each tube was split in three 
aliquots and RNA was isolated with the sampling sys-
tems’ original protocols as well as the modified protocol.

















































Fig. 5 Comparison of the significant probes across the three experiments. a Number of probes preserved in PAXgene (logFC <0; purple) and 
Tempus (logFC >0; blue) for the original protocols and the modified protocol in all three experiments. b Venn diagram of microarray probes having 
significantly different signals (p < 0.05) between PAXgene and Tempus for the modified protocol across all three experiments
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Experiment 3
Samples from the same biobanks as in experiment 2 were 
used, but with a larger sample set: n  =  41 (NOWAC) 
and n =  20 (HUNT3), all females aged between 43 and 
70. RNA was isolated from the samples using the modi-
fied protocol, and otherwise treated the same way as in 
experiment 2.
Sample treatment and RNA isolation
Both the original protocols and the modified protocol 
are divided into four parts: (1) buffer removal, (2) pellet 
washing, (3) running through column and (4) elution. 
Samples isolated with the modified protocol and the 
original PAXgene protocol were treated with DNase to 
remove any traces of genomic DNA.
Original RNA extraction protocols
RNA from samples collected on PAXgene tubes was iso-
lated according to the “Purification of Total RNA from 
human whole Blood Collected into PAXgene Blood RNA 
Tubes” protocol in the PAXgene Blood RNA Kit Hand-
book (PreAnalytiX GmbH, 08/2005, REF: 762174). The 
Tempus tubes were processed according to the “Tempus 
Spin RNA Isolation Kit” protocol (Applied Biosystems, 
2008, Part Number 4379232 Rev. D).
Modified RNA extraction protocol
In the modified protocol (Additional file 5), total content 
in the tubes (blood and preservative in either PAXgene 
or Tempus) was diluted with 1× PBS (1:1 vol of blood: 
1× PBS). The tubes were subsequently vortexed for 30 s 
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Fig. 6 Signal changes and physical characteristics of all probes present on the Illumina HT-12 v4 chip. a Scatter plots showing for all probes on the 
Illumina HT-12 v4 chip, their logFC values from the comparisons of PAXgene and Tempus with the modified protocol on all three experiments. b 
Length, c GC content, and d number of significantly enriched biological terms of transcripts consistently preserved in PAXgene (purple) and Tempus 
(blue) from (a)
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before centrifugation for 60 min (4500 rcf, 4 °C) using a 
swing out rotor. The supernatant was removed and the 
tubes were decanted upside down for 2 min to dry. Buffer 
1 (350 μL) from the PAXgene kit was added and the pel-
let was dissolved by pipetting up and down. The samples 
were transferred to sterile 1.5 mL tubes (Eppendorf AG, 
Hamburg, Germany) before adding Buffer 2 (300 μL) and 
proteinase K (40 μL), both from the PAXgene kit. The 
samples were vortexed and incubated for 10 min at 55 °C 
using a shaker incubator (1200 rpm, Eppendorf thermo-
mixer comfort, Eppendorf ). After a quick spin down, the 
lysate was directly pipetted to a PAXgene spin column 
and centrifuged for 3  min (1500 rcf ). The supernatant 
was transferred to a new tube and 100% ethanol (812 μL, 
1.25 times the present volume) was added and mixed by 
turning the tube upside down. The lysate- and ethanol 
mix was transferred to filter from the mirVana kit (Life 
Technologies, Part Number AM1560), centrifuged for 
15 s (9000 rcf ) and the flow-through was discarded. Since 
the filter has a maximum volume of 700 μL, this process 
was repeated until all the mix was run through. Wash 
solution 1 (700 μL) from the mirVana kit (Life Technolo-
gies) was added and the samples were centrifuged for 15 s 
(9000 rcf ). The flow-through was subsequently discarded 
before 500 μL Wash solution 2/3 (Life Technologies) was 
added. The samples were again centrifuged for 15 s (9000 
rcf ). The flow-through was discarded before treating 
with DNase1 (80 µL) (PreAnalytiX) for 15  min at room 
temperature. The filter was washed with a second round 
of Wash solution 2/3 (500 μL), and centrifuged for 15  s 
(9000 rcf ). The filter was dried for one min by centrifug-
ing (9000 rcf ) before it was transferred to a new collec-
tion tube. To elute the RNA 50, μL pre-heated nuclease 
free water (Tempus kit, Applied Biosystems) was added 
followed by spinning for 30 s (9000 rcf ). The elution step 
was repeated and the tubes were centrifuged for 2 min. 
The eluate was transferred to a new sterile 1.5 mL tube 
(Eppendorf AG) without disturbing the debris. Finally, 
the samples were incubated at 65  °C for 5  min before 
RNA yield and quality were measured. All samples were 
stored at −80 °C.
RNA quality check
The concentration (OD260) and purity (OD260/280 
ratio) of extracted total RNA was measured using Nan-
oDrop ND-1000 spectrophotometer (Thermo Fisher 
Scientific, MA, USA). Agilent 2100 Bioanalyzer (Agi-
lent Technologies, Santa Clara, CA, USA) was used to 
assess the RNA integrity using the Eukaryote total RNA 
6000 Pico LabChip kit and the Eukaryote total RNA Pico 
assay according to the manufacturer’s instructions. The 
RNA integrity numbers (RIN) were calculated using the 
Agilent 2100 Expert Software (Agilent Technologies); 
RIN = 1 indicates low RNA quality and RIN = 10 indi-
cates highest RNA quality.
miRNA detection
Samples from experiment 1 were used to verify the pres-
ence of miRNA by the use of TaqMan-qPCR (Applied 
Biosystems). miRNA was detected by running quanti-
tative real-time PCR (qRT-PCR) on all samples isolated 
from the volunteers. A serial dilution of cervical adeno-
carcinoma (HeLa-S3) total RNA (Ambion Life Tech-
nologies, cat. Nr: AM7852) was used to make a standard 
curve (range: 200 to 0.02 ng/µL). Total RNA (40 ng) was 
reverse transcribed in a 15 µL reaction using TaqMan 
reverse transcription reagents (Applied Biosystems). 
The TaqMan MicroRNA Assay IDs 000391, 001098, 
and 002626 (Applied Biosystems) were used to quantify 
the expression of hsa-miR-16, hsa-miR-181, and hsa-
miR-423, respectively. Quantitative PCR was carried out 
on a StepOnePlus Real-Time PCR System (Applied Bio-
system). The concentration (ng/µL) of miR-16, miR-181 
and miR-423 in the blood samples was calculated from 
the standard curve equation.
Microarray processing
The Illumina TotalPrep RNA Amplification Kit (Ambion 
Inc., Austin, TX, USA) was used to amplify RNA for 
hybridization on Illumina BeadChips. The three experi-
ments used in this study were processed in two separate 
runs. Experiment 1 was run separately from experiment 
2 and 3. Total RNA was used in the first strand cDNA 
synthesis by reverse transcription. Following the second 
strand cDNA synthesis and cDNA purification steps, 
in vitro transcription to synthesize cRNA was carried out 
for 12 h. Biotin-labeled cRNA was hybridised to Illumina 
HumanHT-12 v4 Expression BeadChips (Illumina, Inc., 
San Diego, CA, USA) according to the manufacturer´s 
protocol. Microarrays were scanned with the BeadArray 
Reader (Illumina).
Data and statistical analysis
A total of 106 samples including 3 technical replicates 
were analysed. Illumina BeadArray studio (Illumina) 
was used to handle Illumina data. Data analysis was per-
formed using R (http://cran.r-project.org), together with 
tools from the Bioconductor project (http://bioconduc-
tor.org), Galaxy (http//usegalaxy.org) and UCSC (https://
genome.ucsc.edu/cgi-bin/hgTables). Data from 47323 
probes was transformed and normalized using quantile–
quantile normalization. For differential expression anal-
ysis, functions from the limma package [17] were used. 
The Benjamini-Hochberg procedure was used to correct 
for multiple testing. We used a paired analysis on the 
data from the samples in experiment 1 and non-paired 
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analyses of the data from experiments 2 and 3. Data from 
Menke et  al. [14], was downloaded from (https://www.
ebi.ac.uk/arrayexpress/help/GEO_data.html). We used a 
subset of their data from samples isolated with the origi-
nal protocols and without dexamethasone treatment. 
These data was used in a non-paired analysis against 
our samples from experience 1 isolated with the original 
protocols.
Packages ggplot2 [18], reshape2 [19], gridExtra [20] 
and Vennerable [21] were used for data visualization. 
Enrichment analysis of lists of the probes of interest were 
analysed by gProfiler [22].
Statistical significance of differences between probes 
reproducible across experiments and between different 
sample sets was calculated using Fisher´s exact test. Sig-
nificance of differences (p < 0.05) in correlation between 
average expression as well as logFC between experiment 
1 and 2 for both protocols were calculated with Pear-
son and Spearman equations. Significance of differences 
between the relative expression of miR-16, miR-181, and 
miR-423 between the tubes and protocols was calculated 
using a two-sided paired Student’s t test.
When describing quantity changes from an initial to a 
final value we use log2 fold change (logFC) throughout 
this article.
The five contrasts produced from the statistical analy-
ses were compared with regard to protocols (original 
protocols versus the modified protocol), and with regard 
to reproducibility (each protocol across two and three 
experiments) (Fig. 1; Table 2; Additional file 6).
Transcript length, GC content and biological terms
To investigate length and GC content of transcripts of 
interest, gene symbols for all Illumina ProbeIDs were 
retrieved from the microarray’s Bioconductor annota-
tion package (illuminaHumanv4.db). Transcript IDs 
from the RefSeq database were then retrieved from the 
UCSC Table Browser (https://genome.ucsc.edu/cgi-bin/
hgTables) by uploading and intersecting the gene sym-
bols with the refGene table. In total, the UCSC Table 
Browser identified 39818 of the 47323 probes. The result-
ing list of RefSeq IDs was exported to Galaxy (http://
usegalaxy.org) for further analyses. Galaxy produced the 
FASTA sequence of the respective RNA sequence of the 
imported genes (transcripts). The “geecee” tool was used 
to calculate the GC content of each FASTA sequence, and 
the “FASTA manipulation” tool was used to calculate the 
length of each FASTA sequence. The gProfiler package in 
R was used to identify whether differentially expressed 
genes were significantly enriched within biological terms 
in the GO, KEGG, and REACTOME databases.
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Additional files
Additional file 1. Overview of all samples used in this study and their 
respective information.
Additional file 2. Principal component analysis (PCA) and probe signal 
distributions. (A) Samples plotted in the plane defined by the first (PC1) 
and second (PC2) principal components from a PCA analysis of all the 
gene expression data. Differences between the first and the second 
microarray run are shown as the first component in the PCA, explaining 
39% of the differences in the samples due to batch effects. The second 
component reveals that differences between the sampling systems con-
tribute 14% of the differences between the samples. (B) Density plot of 
the probe signals from the first and second microarray run. There is a clear 
shift in the probe signal distribution, seen as a shift in the peaks, between 
the two runs.
Additional file 3. Behaviour of all probes present on the Illumina HT-12 
v4 chip. LogFC values from the analysis of PAXgene and Tempus in combi-
nation with the original protocol of all the probes present on the Illumina 
HT-12 v4 chip are compared between experiment 1 and 2.
Additional file 4. Comparison of logFC values between experiment 1 
and the study by Menke et al. [4]. Scatter plot of the logFC values from 
experiment 1 when the original protocols were used and the logFC values 
when the original protocols were used in the Menke et al. study. The plot 
includes all probes that were common between this study and Menke 
et al.
Additional file 5. Flowchart of the modified protocol. The modified pro-
tocol consists of three parts: (A) collecting blood, (B) processing stabilized 
blood, and (C) isolating RNA. The overview of the protocol is outlined in 
the first column (“Process”), and the reagents for each step is given in the 
second column (“Reagents”). The modified protocol is assembled from 
three kits: Tempus (blue), PAXgene (cerise), and mirVana (green); note that 
the reagents used from the Tempus kit are universal and can be replaced 
with equivalent reagents from other suppliers.
Additional file 6. Tables of probes found significant between PAXgene 
and Tempus. The workbook contains 5 sheets of tables, one for each 
contrast (Fig. 1). Each table is the output from the function topTable 
from limma and contains all significant probes identified in the contrast. 
The columns are the probe ID (ProbeID); the gene symbol for the gene 
targeted by the probe (TargetID); the log2 fold change (logFC) of the 
Tempus–PAXgene contrast; the average probe signal (AveExpr); the 
moderated t-statistic (t), corresponding p value (P.Value), and Benjamin-
Hochberg adjusted p-value (adj. P. Val); the log-odds that the gene is 
differentially expressed (B); and the Illumina-specific probe ID (ilmnid).
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